132 HiJacK vitiligo: JAK3 and TEC family kinase inhibition in the pathogenesis and treatment of vitiligo
Journal of Investigative Dermatology · 2025-11 · 145 (11) · e52
DOI: 10.1016/j.jid.2025.09.147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Investigative Dermatology, 2025-11. Verfasst von Emma Holtappels und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Holtappels, E., Chielie, S., Uden, N. V., Licher, T., Bekkenk, M., Luiten, R., & Bakker, W. (2025). 132 HiJacK vitiligo: JAK3 and TEC family kinase inhibition in the pathogenesis and treatment of vitiligo. Journal of Investigative Dermatology, 145(11), e52. https://doi.org/10.1016/j.jid.2025.09.147
Vancouver
Holtappels E, Chielie S, Uden NV, Licher T, Bekkenk M, Luiten R, et al. 132 HiJacK vitiligo: JAK3 and TEC family kinase inhibition in the pathogenesis and treatment of vitiligo. Journal of Investigative Dermatology. 2025;145(11):e52. doi:10.1016/j.jid.2025.09.147
BibTeX
@article{Holtappels2025,
author = {Holtappels, Emma and Chielie, Saskia and Uden, Nathalie van and Licher, Tessa and Bekkenk, Marcel and Luiten, Rosalie and Bakker, Walbert},
title = {132 HiJacK vitiligo: JAK3 and TEC family kinase inhibition in the pathogenesis and treatment of vitiligo},
journal = {Journal of Investigative Dermatology},
year = {2025},
volume = {145},
number = {11},
pages = {e52},
doi = {10.1016/j.jid.2025.09.147}
}
EUVIMED